CTOs on the Move

Treasure Coast Radiation Oncology, Pa

www.tcropa.com

 
Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tcropa.com
  • 2107 SE Ocean Blvd
    Stuart, FL USA 34996
  • Phone: 772.781.5780

Executives

Name Title Contact Details

Similar Companies

BNBI

Managed by Battelle National Biodefense Institute (BNBI) as a Federally Funded Research and Development Center (FFRDC), National Biodefense Analysis and Countermeasures Center is the first laboratory built for DHS – a national resource to understand th...

Center for Functional Genomics

Center for Functional Genomics is a Rensselaer, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurinia Pharmaceuticals

Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.

Kai Pharmaceuticals

Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.